<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-04-29T00:39:07Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10030878" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10030878</identifier>
        <datestamp>2023-03-22</datestamp>
        <setSpec>sageopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Dent Res</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Dent Res</journal-id>
              <journal-id journal-id-type="publisher-id">JDR</journal-id>
              <journal-id journal-id-type="hwp">spjdr</journal-id>
              <journal-title-group>
                <journal-title>Journal of Dental Research</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0022-0345</issn>
              <issn pub-type="epub">1544-0591</issn>
              <publisher>
                <publisher-name>SAGE Publications</publisher-name>
                <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10030878</article-id>
              <article-id pub-id-type="pmcid">PMC10030878</article-id>
              <article-id pub-id-type="pmc-uid">10030878</article-id>
              <article-id pub-id-type="pmid">36942423</article-id>
              <article-id pub-id-type="pmid">36942423</article-id>
              <article-id pub-id-type="doi">10.1177/00220345231156415</article-id>
              <article-id pub-id-type="publisher-id">10.1177_00220345231156415</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Reports</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Clinical</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Efficacy of a Mouthwash Containing CHX and CPC in SARS-CoV-2–Positive
Patients: A Randomized Controlled Clinical Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bonn</surname>
                    <given-names>E.L.</given-names>
                  </name>
                  <xref rid="aff1-00220345231156415" ref-type="aff">1</xref>
                  <xref rid="aff2-00220345231156415" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rohrhofer</surname>
                    <given-names>A.</given-names>
                  </name>
                  <xref rid="aff3-00220345231156415" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Audebert</surname>
                    <given-names>F.X.</given-names>
                  </name>
                  <xref rid="aff4-00220345231156415" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lang</surname>
                    <given-names>H.</given-names>
                  </name>
                  <xref rid="aff4-00220345231156415" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Auer</surname>
                    <given-names>D.L.</given-names>
                  </name>
                  <xref rid="aff1-00220345231156415" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Scholz</surname>
                    <given-names>K.J.</given-names>
                  </name>
                  <xref rid="aff1-00220345231156415" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schuster</surname>
                    <given-names>P.</given-names>
                  </name>
                  <xref rid="aff2-00220345231156415" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wenzel</surname>
                    <given-names>J.J.</given-names>
                  </name>
                  <xref rid="aff3-00220345231156415" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hiller</surname>
                    <given-names>K.-A.</given-names>
                  </name>
                  <xref rid="aff1-00220345231156415" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Buchalla</surname>
                    <given-names>W.</given-names>
                  </name>
                  <xref rid="aff1-00220345231156415" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3623-3183</contrib-id>
                  <name>
                    <surname>Gottsauner</surname>
                    <given-names>J.M.</given-names>
                  </name>
                  <xref rid="aff5-00220345231156415" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vielsmeier</surname>
                    <given-names>V.</given-names>
                  </name>
                  <xref rid="aff6-00220345231156415" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schmidt</surname>
                    <given-names>B.</given-names>
                  </name>
                  <xref rid="aff2-00220345231156415" ref-type="aff">2</xref>
                  <xref rid="aff3-00220345231156415" ref-type="aff">3</xref>
                  <xref rid="fn1-00220345231156415" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1750-7380</contrib-id>
                  <name>
                    <surname>Cieplik</surname>
                    <given-names>F.</given-names>
                  </name>
                  <xref rid="aff1-00220345231156415" ref-type="aff">1</xref>
                  <xref rid="fn1-00220345231156415" ref-type="author-notes">*</xref>
                  <xref rid="corresp1-00220345231156415" ref-type="corresp"/>
                </contrib>
              </contrib-group>
              <aff id="aff1-00220345231156415"><label>1</label>Department of Conservative Dentistry and
Periodontology, University Hospital Regensburg, Regensburg, Germany</aff>
              <aff id="aff2-00220345231156415"><label>2</label>Institute of Medical Microbiology and
Hygiene, University of Regensburg, Regensburg, Germany</aff>
              <aff id="aff3-00220345231156415"><label>3</label>Institute of Clinical Microbiology and
Hygiene, University Hospital Regensburg, Regensburg, Germany</aff>
              <aff id="aff4-00220345231156415"><label>4</label>Praxiszentrum Alte Mälzerei, Regensburg,
Germany</aff>
              <aff id="aff5-00220345231156415"><label>5</label>Department of Oral and Maxillofacial Surgery,
University Hospital Regensburg, Regensburg, Germany</aff>
              <aff id="aff6-00220345231156415"><label>6</label>Department of Otorhinolaryngology, University
Hospital Regensburg, Regensburg, Germany</aff>
              <author-notes>
                <corresp id="corresp1-00220345231156415">F. Cieplik, Department of Conservative Dentistry
and Periodontology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053
Regensburg, Germany. Email: <email>fabian.cieplik@ukr.de</email></corresp>
                <fn fn-type="equal" id="fn1-00220345231156415">
                  <label>*</label>
                  <p>Authors contributing equally to this article.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>21</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>21</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>102</volume>
              <issue>6</issue>
              <fpage>608</fpage>
              <lpage>615</lpage>
              <permissions>
                <copyright-statement>© International Association for Dental Research and American
Association for Dental, Oral, and Craniofacial Research 2023</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder content-type="society">International &amp; American Associations for
Dental Research</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This article is distributed under the terms of the Creative Commons Attribution
4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use,
reproduction and distribution of the work without further permission provided the
original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <p>Soon after the outbreak of the coronavirus disease 2019 (COVID-19) pandemic,
preprocedural mouthwashes were recommended for temporarily reducing intraoral viral load
and infectivity of individuals potentially infected with the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in order to protect medical personnel. Particularly,
the antiseptic cetylpyridinium chloride (CPC) has shown virucidal effects against
SARS-CoV-2 in vitro. Therefore, the aim of this randomized controlled clinical trial was
to investigate the efficacy of a commercially available mouthwash containing CPC and
chlorhexidine digluconate (CHX) at 0.05% each in SARS-CoV-2–positive patients as compared
to a placebo mouthwash. Sixty-one patients who tested positive for SARS-CoV-2 with onset
of symptoms within the last 72 h were included in this study. Oropharyngeal specimens were
taken at baseline, whereupon patients had to gargle mouth and throat with 20 mL test or
placebo (0.9% NaCl) mouthwash for 60 s. After 30 min, further oropharyngeal specimens were
collected. Viral load was analyzed by quantitative reverse transcriptase polymerase chain
reaction, and infectivity of oropharyngeal specimens was analyzed by virus rescue in cell
culture and quantified via determination of tissue culture infectious doses 50%
(TCID<sub>50</sub>). Data were analyzed nonparametrically (α = 0.05). Viral load
slightly but significantly decreased upon gargling in the test group (<italic toggle="yes">P</italic> =
0.0435) but not in the placebo group. Viral infectivity as measured by TCID<sub>50</sub>
also significantly decreased in the test group (<italic toggle="yes">P</italic> = 0.0313), whereas
there was no significant effect but a trend in the placebo group. Furthermore, it was
found that the specimens from patients with a vaccine booster exhibited significantly
lower infectivity at baseline as compared to those without vaccine booster
(<italic toggle="yes">P</italic> = 0.0231). This study indicates that a preprocedural mouthwash
containing CPC and CHX could slightly but significantly reduce the viral load and
infectivity in SARS-CoV-2–positive patients. Further studies are needed to corroborate
these results and investigate whether the observed reductions in viral load and
infectivity could translate into clinically useful effects in reducing COVID-19
transmission (German Clinical Trials Register DRKS00027812).</p>
              </abstract>
              <kwd-group>
                <kwd>COVID-19</kwd>
                <kwd>antiseptic</kwd>
                <kwd>cetylpyridinium chloride</kwd>
                <kwd>chlorhexidine</kwd>
                <kwd>mouthwash</kwd>
                <kwd>SARS-CoV-2</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="award1-00220345231156415">
                  <funding-source id="funding1-00220345231156415">
                    <institution-wrap>
                      <institution>Dentaid S.L., Barcelona, Spain</institution>
                      <institution-id/>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>typesetter</meta-name>
                  <meta-value>ts1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="section1-00220345231156415">
              <title>Introduction</title>
              <p>Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), an enveloped single-stranded RNA virus, which is primarily
transmitted by direct contact or airborne transmission via droplets and aerosols (<xref rid="bibr37-00220345231156415" ref-type="bibr">van Doremalen et al. 2020</xref>). It is
known that the viral load of SARS-CoV-2 is exceptionally high in the oral cavity and the
pharynx due to high abundance of cells expressing the transmembrane angiotensin-converting
enzyme 2 (ACE-2), which is necessary for entrance and fusion of the SARS-CoV-2 viral
envelope with target cells (<xref rid="bibr16-00220345231156415" ref-type="bibr">Herrera et
al. 2020</xref>; <xref rid="bibr33-00220345231156415" ref-type="bibr">Peng et al.
2020</xref>; <xref rid="bibr39-00220345231156415" ref-type="bibr">Wölfel et al.
2020</xref>; <xref rid="bibr40-00220345231156415" ref-type="bibr">Zou et al.
2020</xref>).</p>
              <p>Therefore, right after onset of the COVID-19 pandemic, it was discussed that health care
professionals (HCPs) from disciplines with close patient contact, where no face masks can be
worn by the patients during examination and therapy, could be at high risk for nosocomial
infection with SARS-CoV-2, including dentists, maxillofacial surgeons, and
otorhinolaryngologists (<xref rid="bibr27-00220345231156415" ref-type="bibr">Meng et al.
2020</xref>; <xref rid="bibr33-00220345231156415" ref-type="bibr">Peng et al.
2020</xref>). Although recent data suggest that dental practice personnel are at no higher
risk for infection with SARS-CoV-2 as compared to the general public (<xref rid="bibr2-00220345231156415" ref-type="bibr">Araujo et al. 2021</xref>; <xref rid="bibr28-00220345231156415" ref-type="bibr">Mksoud et al. 2022</xref>), there are also reports stating
high infection risks for dentists as well as for HCPs from other specialties (<xref rid="bibr32-00220345231156415" ref-type="bibr">Nguyen et al. 2020</xref>; <xref rid="bibr34-00220345231156415" ref-type="bibr">Sarapultseva et al. 2021</xref>). Among
other measures such as personal protective equipment, preprocedural mouthwashes have been
discussed and recommended from the early stages of the pandemic for temporarily reducing the
intraoral viral load and infectivity in SARS-CoV-2–positive individuals (<xref rid="bibr14-00220345231156415" ref-type="bibr">Gottsauner et al. 2020</xref>; <xref rid="bibr16-00220345231156415" ref-type="bibr">Herrera et al. 2020</xref>; <xref rid="bibr25-00220345231156415" ref-type="bibr">Meister et al. 2020</xref>; <xref rid="bibr27-00220345231156415" ref-type="bibr">Meng et al. 2020</xref>; <xref rid="bibr33-00220345231156415" ref-type="bibr">Peng et al. 2020</xref>; <xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>). While some
studies could quickly demonstrate that several antiseptics had a high virucidal efficacy to
SARS-CoV-2 in vitro (<xref rid="bibr5-00220345231156415" ref-type="bibr">Bidra et al.
2020</xref>; <xref rid="bibr25-00220345231156415" ref-type="bibr">Meister et al.
2020</xref>; <xref rid="bibr31-00220345231156415" ref-type="bibr">Muñoz-Basagoiti et al.
2021</xref>; <xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al.
2022</xref>), the clinical translation of these in vitro results is still not clear. The
few clinical trials that have been conducted come to different conclusions: some advocate
the use of antiseptic mouthwashes in SARS-CoV-2–positive individuals, while others do not
(<xref rid="bibr14-00220345231156415" ref-type="bibr">Gottsauner et al. 2020</xref>; <xref rid="bibr7-00220345231156415" ref-type="bibr">Chaudhary et al. 2021</xref>; <xref rid="bibr11-00220345231156415" ref-type="bibr">Domênico et al. 2021</xref>; <xref rid="bibr12-00220345231156415" ref-type="bibr">Ferrer et al. 2021</xref>; <xref rid="bibr17-00220345231156415" ref-type="bibr">Huang and Huang 2021</xref>; <xref rid="bibr35-00220345231156415" ref-type="bibr">Seneviratne et al. 2021</xref>; <xref rid="bibr1-00220345231156415" ref-type="bibr">Alemany et al. 2022</xref>; <xref rid="bibr4-00220345231156415" ref-type="bibr">Barrueco et al. 2022</xref>; <xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>). This is mainly
due to the lack of virus rescue in cell culture, which is essential to assess viral
infectivity, whereas quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
just detects viral RNA copies by their presence but cannot give an indication on whether
these particles are infectious or not (<xref rid="bibr12-00220345231156415" ref-type="bibr">Ferrer et al. 2021</xref>; <xref rid="bibr4-00220345231156415" ref-type="bibr">Barrueco
et al. 2022</xref>; <xref rid="bibr8-00220345231156415" ref-type="bibr">Cieplik and
Jakubovics 2022</xref>; <xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et
al. 2022</xref>).</p>
              <p>Chlorhexidine digluconate (CHX) and cetylpyridinium chloride (CPC) can be considered the
antiseptics that are most commonly used in dental practice (<xref rid="bibr9-00220345231156415" ref-type="bibr">Cieplik et al. 2019</xref>; <xref rid="bibr24-00220345231156415" ref-type="bibr">Marui et al. 2019</xref>; <xref rid="bibr22-00220345231156415" ref-type="bibr">Mao et al. 2020</xref>). Besides a high antibacterial
efficacy against planktonic bacteria in saliva and aerosols (<xref rid="bibr24-00220345231156415" ref-type="bibr">Marui et al. 2019</xref>), particularly CPC yielded
promising in vitro data against SARS-CoV-2, based on disruption of the viral envelope, which
prevents fusion with the target cell (<xref rid="bibr20-00220345231156415" ref-type="bibr">Koch-Heier et al. 2021</xref>; <xref rid="bibr31-00220345231156415" ref-type="bibr">Muñoz-Basagoiti et al. 2021</xref>; <xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>).</p>
              <p>Therefore, the aim of the present study was to investigate the efficacy of a commercially
available mouthwash containing CHX and CPC regarding the reduction of the intraoral viral
load and infectivity in SARS-CoV-2–positive patients as compared to a placebo mouthwash by
using qRT-PCR for detection of viral load and virus rescue in cell culture for evaluation of
viral infectivity. In addition, viral load and infectivity were also assessed with respect
to the COVID-19 vaccination status of the patients.</p>
            </sec>
            <sec sec-type="materials|methods" id="section2-00220345231156415">
              <title>Materials and Methods</title>
              <sec id="section3-00220345231156415">
                <title>Study Design and Ethical Considerations</title>
                <p>The present study is a prospective randomized controlled clinical trial investigating the
efficacy of a commercially available mouthwash containing 0.05% CPC and 0.05% CHX
(PerioAid Active Control; Dentaid SL) as compared to a placebo mouthwash (0.9% NaCl) on
reducing the intraoral viral load and infectivity in SARS-CoV-2–positive patients.</p>
                <p>The study design followed the requirements outlined in the Consolidated Standards of
Reporting Trials (CONSORT) 2010 statement and was approved by the internal review board of
the University of Regensburg (ref. 20-1787_3-101) in accordance with the 1964 Declaration
of Helsinki and its later amendments or comparable ethical standards. The study has been
prospectively registered at the German Clinical Trials Register (ref. DRKS00027812).</p>
              </sec>
              <sec id="section4-00220345231156415">
                <title>Inclusion and Exclusion Criteria</title>
                <p>Patients admitted to a private practice with a special focus on infectious diseases
(Praxiszentrum Alte Mälzerei, Regensburg, Germany) were screened for inclusion in this
study. To be included, patients had to exhibit COVID-19–like symptoms for not longer than
72 h as well as a positive antigen point-of-care test (SARS-CoV-2 Rapid Antigen Test;
Roche) at the time of inclusion in the study. Exclusion criteria were indication for
intubation or mechanical ventilation and severe stomatitis. Written informed consent was
obtained from all individual participants included in the study. Besides demographic data
such as age and gender, also anamnestic data such as COVID-19 vaccination status, history
of infection with SARS-CoV-2, and time periods since the last vaccine shot or infection
were recorded.</p>
              </sec>
              <sec id="section5-00220345231156415">
                <title>Clinical Procedures</title>
                <p>Patients were randomly assigned to test or placebo group using a randomization table
generated by SPSS, version 26 (SPSS, Inc.), immediately after the SARS-CoV-2 antigen test
turned out to be positive. Then, baseline (BL) oropharyngeal specimens were acquired by
letting the patients gargle their mouth and throat with 10 mL 0.9% NaCl for 20 s. These
specimens were used for qRT-PCR–based confirmation of infection with SARS-CoV-2 and
genotyping and as baseline specimens for determination of viral load and determination of
tissue culture infection doses 50% (TCID<sub>50</sub>). Immediately afterward, patients
had to rinse their mouth and throat with 20 mL test (PerioAid Active Control; Dentaid SL)
or placebo mouthwash (0.9% NaCl) by gargling their mouth and their throat for 60 s,
whereby they were blinded to the respective group. Thirty minutes after gargling, a
further oropharyngeal specimen was obtained by asking the patients to gargle their mouth
and throat with 10 mL 0.9% NaCl for 20 s. The 30-min postrinse period was chosen to
reflect routine dental and otorhinolaryngological procedures. The investigators of
qRT-PCR, genotyping, and virus culture experiments were blinded to the respective
group.</p>
              </sec>
              <sec id="section6-00220345231156415">
                <title>QRT-PCR–Based Analysis of Viral Load and Genotyping</title>
                <p>Nucleic acids were isolated from oropharyngeal specimens using EZ1 Virus Mini Kit v2.0
with EZ1 Advanced XL system (Qiagen), as described previously (<xref rid="bibr14-00220345231156415" ref-type="bibr">Gottsauner et al. 2020</xref>; <xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>). Viral RNA was amplified
using a published SARS-CoV-2 E gene qRT-PCR protocol (<xref rid="bibr10-00220345231156415" ref-type="bibr">Corman et al. 2020</xref>) on the StepOnePlus qRT-PCR
System (Thermo Fisher Scientific). For quantification, a standard curve was prepared from
in vitro transcribed RNA. Genotyping of SARS-CoV-2 RNA was performed using specific
VirSNiP assays (TIB Molbiol). These kits allow identifying the virus genotype by testing
for characteristic single-nucleotide polymorphisms in the spike gene by means of qRT-PCR
and melting curve analysis with specific fluorescent molecular probes. Spike positions
p.E484A (g.23013A &gt; C) p.L452R (g.22917T &gt; G) and p.S371L/p.S373P (g.22673T &gt; C,
g.22674C &gt; T) were analyzed.</p>
              </sec>
              <sec id="section7-00220345231156415">
                <title>Virus Culture and Determination of TCID<sub>50</sub></title>
                <p>Virus culture and determination of TCID<sub>50</sub> was performed as described before
(<xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>).
SARS-CoV-2 was isolated from all oropharyngeal specimens at BL and 30 min after gargling.
Vero cells were cultivated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal calf serum (Sigma-Aldrich), 90 U/mL streptomycin, 0.3 mg/mL
glutamine, 200 U/mL penicillin, and 2.5 μg/mL amphotericin B (PAN Biotech). Viral titers
of the oropharyngeal specimens were determined by endpoint dilution on Vero cells and
calculating TCID<sub>50</sub> as plaque-forming units (PFU) per mL.</p>
              </sec>
              <sec id="section8-00220345231156415">
                <title>Data Analysis</title>
                <p>Data are reported as median values (with first and third quartiles) or proportions
(numbers of patients), respectively. Data were analyzed statistically by applying
nonparametric procedures using GraphPad Prism, version 9 (GraphPad Software). Mann–Whitney
<italic toggle="yes">U</italic> tests or χ<sup>2</sup> tests were used for pairwise comparisons
between independent groups, while Wilcoxon signed-rank tests were used for pairwise
comparisons for related groups over time between BL and 30 min. The significance level was
set at α = 0.05.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="section9-00220345231156415">
              <title>Results</title>
              <sec id="section10-00220345231156415">
                <title>Patient Population</title>
                <p>Between January 4, 2022, and February 22, 2022, 61 SARS-CoV-2–positive patients were
included in this study, of whom 31 were randomly assigned to the test group and 30 to the
placebo group. <xref rid="fig1-00220345231156415" ref-type="fig">Figure 1</xref> shows the
CONSORT flow of patients for this study, and the <xref rid="table1-00220345231156415" ref-type="table">Table</xref> summarizes the patient characteristics of
all individual patients included in this study. The median (first, third quartile) age was
29 (25, 42) years for all included patients. Of the participants, 86.9% had received at
least 1 COVID-19 vaccination dose, but most had received 2 or 3 vaccine shots. Seven
patients had a history of a SARS-CoV-2 infection (confirmed by qRT-PCR), resulting in a
significant difference between test and placebo groups (<italic toggle="yes">P</italic> = 0.04).
Besides that, there were no significant differences between test and placebo groups
regarding patient characteristics.</p>
                <fig position="float" id="fig1-00220345231156415">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Flow of patients through the stages of this study.</p>
                  </caption>
                  <graphic xlink:href="10.1177_00220345231156415-fig1" position="float"/>
                </fig>
                <table-wrap position="float" id="table1-00220345231156415">
                  <label>Table.</label>
                  <caption>
                    <p>Patient Characteristics.</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_00220345231156415-table1" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Characteristic</th>
                          <th align="center" rowspan="1" colspan="1">All Patients (<italic toggle="yes">n</italic> = 61)</th>
                          <th align="center" rowspan="1" colspan="1">Test Group (<italic toggle="yes">n</italic> = 31)</th>
                          <th align="center" rowspan="1" colspan="1">Placebo Group (<italic toggle="yes">n</italic> = 30)</th>
                          <th align="center" rowspan="1" colspan="1">Significant Differences</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">Age, median (first, third quartile), y</td>
                          <td rowspan="1" colspan="1">29 (25, 42)</td>
                          <td rowspan="1" colspan="1">29 (26, 36.5)</td>
                          <td rowspan="1" colspan="1">29.5 (25, 48)</td>
                          <td align="center" rowspan="1" colspan="1">—</td>
                        </tr>
                        <tr>
                          <td colspan="5" rowspan="1">Sex</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Female</td>
                          <td rowspan="1" colspan="1">49.2 (30)</td>
                          <td rowspan="1" colspan="1">45.2 (14)</td>
                          <td rowspan="1" colspan="1">53.3 (16)</td>
                          <td align="center" rowspan="2" colspan="1">—</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Male</td>
                          <td rowspan="1" colspan="1">50.8 (31)</td>
                          <td rowspan="1" colspan="1">54.8 (17)</td>
                          <td rowspan="1" colspan="1">46.7 (14)</td>
                        </tr>
                        <tr>
                          <td colspan="5" rowspan="1">Vaccination status</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Vaccinated</td>
                          <td rowspan="1" colspan="1">86.9 (53)</td>
                          <td rowspan="1" colspan="1">93.5 (29)</td>
                          <td rowspan="1" colspan="1">80 (24)</td>
                          <td align="center" rowspan="5" colspan="1">—</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> 3 vaccine shots</td>
                          <td rowspan="1" colspan="1">57.4 (35)</td>
                          <td rowspan="1" colspan="1">67.7 (21)</td>
                          <td rowspan="1" colspan="1">46.7 (14)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> 2 vaccine shots</td>
                          <td rowspan="1" colspan="1">26.2 (16)</td>
                          <td rowspan="1" colspan="1">25.8 (8)</td>
                          <td rowspan="1" colspan="1">26.7 (8)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> 1 vaccine shot</td>
                          <td rowspan="1" colspan="1">3.3 (2)</td>
                          <td align="center" rowspan="1" colspan="1">—</td>
                          <td rowspan="1" colspan="1">6.7 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Nonvaccinated</td>
                          <td rowspan="1" colspan="1">13.1 (8)</td>
                          <td rowspan="1" colspan="1">6.5 (2)</td>
                          <td rowspan="1" colspan="1">20 (6)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Period since last vaccination, median (first, third quartile), d</td>
                          <td rowspan="1" colspan="1">67 (46, 101)</td>
                          <td rowspan="1" colspan="1">62 (43, 87)</td>
                          <td rowspan="1" colspan="1">73.5 (49, 122.3)</td>
                          <td align="center" rowspan="1" colspan="1">—</td>
                        </tr>
                        <tr>
                          <td colspan="5" rowspan="1">COVID-19 infection status</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Previous infection</td>
                          <td rowspan="1" colspan="1">11.5 (7)</td>
                          <td rowspan="1" colspan="1">3.2 (1)</td>
                          <td rowspan="1" colspan="1">20 (6)</td>
                          <td rowspan="2" colspan="1">0.04</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> No previous infection</td>
                          <td rowspan="1" colspan="1">88.5 (54)</td>
                          <td rowspan="1" colspan="1">96.8 (30)</td>
                          <td rowspan="1" colspan="1">80 (24)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Period since previous COVID-19 infection, median (first, third quartile),
d</td>
                          <td rowspan="1" colspan="1">118 (99, 228.5)</td>
                          <td rowspan="1" colspan="1">392<sup><xref rid="table-fn3-00220345231156415" ref-type="table-fn">a</xref></sup></td>
                          <td rowspan="1" colspan="1">117.5 (90, 148.8)</td>
                          <td rowspan="1" colspan="1">NA</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn1-00220345231156415">
                      <p>Values are presented as % (<italic toggle="yes">n</italic>) unless otherwise indicated.
Statistically significant differences from pairwise comparisons between test and
placebo group (χ<sup>2</sup> tests; α = 0.05) are indicated. <italic toggle="yes">P</italic>
value, significant (<italic toggle="yes">P</italic> ≤ 0.05).</p>
                    </fn>
                    <fn id="table-fn2-00220345231156415">
                      <p>COVID-19, coronavirus disease 2019; NA, not applicable; —, not significant
(<italic toggle="yes">P</italic> &gt; 0.05).</p>
                    </fn>
                    <fn id="table-fn3-00220345231156415">
                      <label>a</label>
                      <p>Single values (for <italic toggle="yes">n</italic> = 1).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="section11-00220345231156415">
                <title>Viral Load</title>
                <p>The assessment of the viral load via qRT-PCR showed a median (first, third quartile)
viral load of 1.2 × 10<sup>6</sup> (8.3 × 10<sup>4</sup>; 7.5 × 10<sup>6</sup>) viral RNA
copies/mL for the test group and of 5.1 × 10<sup>5</sup> (2 × 10<sup>4</sup>; 1.4 ×
10<sup>7</sup>) copies/mL for the placebo group at baseline. The specimens after 30 min
exhibited a median viral load of 3.7 × 10<sup>5</sup> (3.8 × 10<sup>4</sup>; 2.8 ×
10<sup>6</sup>) copies/mL for the test group and 1.5 × 10<sup>5</sup> (2.5 ×
10<sup>4</sup>; 8.9 × 10<sup>6</sup>) copies/mL for the placebo group. There were no
significant differences between groups at either time point. However, as compared to
baseline, there was a decrease by 0.5 log<sub>10</sub> in both groups after the mouthwash,
which was found significant in the test group (<italic toggle="yes">P</italic> = 0.0435) but not in the
placebo group (<italic toggle="yes">P</italic> = 0.5291; <xref rid="fig2-00220345231156415" ref-type="fig">Fig. 2A</xref>).</p>
                <fig position="float" id="fig2-00220345231156415">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Effects of test and placebo mouthwash on viral load and infectivity. (<bold>A</bold>)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA (copies per mL) as
detected by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
from the oropharyngeal specimens taken at baseline (BL) and 30 min after the test
(<italic toggle="yes">n</italic> = 31) or placebo mouthwash (<italic toggle="yes">n</italic> = 30). There was
a statistically significant reduction in viral load in the test group between BL and
30 min (Wilcoxon signed-rank test; α = 0.05). (<bold>B</bold>) Infectious SARS-CoV-2
particles (plaque-forming units [PFU] per mL) as determined by virus culture from the
oropharyngeal specimens taken at BL and 30 min after the test (<italic toggle="yes">n</italic> = 6)
or placebo mouthwash (<italic toggle="yes">n</italic> = 9). There was a statistically significant
reduction in viral infectivity in the test group and a trend in the placebo group
(Wilcoxon signed-rank test; α = 0.05).</p>
                  </caption>
                  <graphic xlink:href="10.1177_00220345231156415-fig2" position="float"/>
                </fig>
              </sec>
              <sec id="section12-00220345231156415">
                <title>Viral Genotyping</title>
                <p>In 10 of the 61 patients, viral genotyping was performed by testing for characteristic
single-nucleotide polymorphisms in the SARS-CoV-2 spike gene. The samples of these
patients harbored mutations specific for variant-of-concern (VOC) omicron (E484A and/or
S371L/P in combination with wildtype at position L452), being representative for the
ongoing omicron wave in Germany at the time of patient recruitment.</p>
              </sec>
              <sec id="section13-00220345231156415">
                <title>Viral Infectivity</title>
                <p>The viral infectivity was assessed by viral culture and determination of
TCID<sub>50</sub>. At baseline, 6 specimens of the test group and 9 of the placebo group
showed replicating virus. Accordingly, a median (first, third quartile) baseline
TCID<sub>50</sub> of 24 (7.5, 160.8) PFU/mL was detected for the test group and 6 (1,
50) PFU/mL for the placebo group. The specimens 30 min after the mouthwash showed a median
TCID<sub>50</sub> of 1 (1, 1.5) PFU/mL for the test group and 1.7 (1, 3.3) PFU/mL for
the placebo group. There were no significant differences between groups at either time
point. However, as compared to baseline, there was a significant decrease in viral
infectivity in the test group by 1.4 log<sub>10</sub> (<italic toggle="yes">P</italic> = 0.0313),
whereas there was a nonsignificant decrease by 0.6 log<sub>10</sub> in the placebo group
(<italic toggle="yes">P</italic> = 0.0977) (<xref rid="fig2-00220345231156415" ref-type="fig">Fig.
2B</xref>).</p>
              </sec>
              <sec id="section14-00220345231156415">
                <title>Effects of Vaccination Status on Baseline Viral Load and Infectivity</title>
                <p>When comparing the baseline viral load and infectivity of patients with 2 vaccine shots
to those with 3 vaccine shots, the latter exhibited a slightly but not significantly lower
viral load but a significantly decreased viral infectivity (<italic toggle="yes">P</italic> = 0.0231;
<xref rid="fig3-00220345231156415" ref-type="fig">Fig. 3</xref>).</p>
                <fig position="float" id="fig3-00220345231156415">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Viral load and infectivity with respect to vaccination status. (<bold>A</bold>)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA (copies per mL) as
detected by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
from the baseline oropharyngeal specimens. Depiction of numbers of vaccine shots (0,
1, 2, 3) and history of natural infection (yes, no). (<bold>B</bold>) Infectious
SARS-CoV-2 particles (plaque-forming units [PFU] per mL) as determined by virus
culture from the baseline oropharyngeal specimens. Depiction of numbers of vaccine
shots (0, 1, 2, 3) and history of natural infection (yes, no). Oropharyngeal specimens
taken from individuals with 3 vaccine shots exhibited significantly less infectious
particles than those with just 2 vaccine shots (Mann–Whitney <italic toggle="yes">U</italic> test;
α = 0.05).</p>
                  </caption>
                  <graphic xlink:href="10.1177_00220345231156415-fig3" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="section15-00220345231156415">
              <title>Discussion</title>
              <p>Although the use of mouthwashes has been discussed as a potential measure to reduce
transmission of SARS-CoV-2 since the beginning of the COVID-19 pandemic, the clinical
evidence is still limited, particularly as there are only very few studies assessing their
effects on viral infectivity by virus rescue in cell culture (<xref rid="bibr14-00220345231156415" ref-type="bibr">Gottsauner et al. 2020</xref>; <xref rid="bibr1-00220345231156415" ref-type="bibr">Alemany et al. 2022</xref>; <xref rid="bibr4-00220345231156415" ref-type="bibr">Barrueco et al. 2022</xref>; <xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>). Thus, we conducted a
randomized placebo-controlled clinical trial investigating a commercially available
mouthwash containing 0.05% CPC and 0.05% CHX in SARS-CoV-2–positive patients and analyzed
not only the viral load by qRT-PCR but also the viral infectivity by virus rescue in cell
culture and determination of TCID<sub>50</sub>.</p>
              <p>CHX and CPC can be considered gold-standard antiseptics in dentistry and have a broad range
of application in mouthwashes or other oral care products (<xref rid="bibr9-00220345231156415" ref-type="bibr">Cieplik et al. 2019</xref>; <xref rid="bibr22-00220345231156415" ref-type="bibr">Mao et al. 2020</xref>). While it is well known that the
antibacterial efficacy of cationic antiseptics is limited toward mature oral biofilms mostly
due to the biofilm matrix, they are highly effective toward planktonic bacteria such as
those in saliva (<xref rid="bibr9-00220345231156415" ref-type="bibr">Cieplik et al.
2019</xref>; <xref rid="bibr22-00220345231156415" ref-type="bibr">Mao et al. 2020</xref>;
<xref rid="bibr18-00220345231156415" ref-type="bibr">Jakubovics et al. 2021</xref>).
Accordingly, it has been shown that preprocedural mouthwashes with CHX or CPC can reduce the
numbers of viable bacteria in aerosols generated during dental treatment, thus potentially
contributing to infection control in dental practice (<xref rid="bibr24-00220345231156415" ref-type="bibr">Marui et al. 2019</xref>; <xref rid="bibr21-00220345231156415" ref-type="bibr">Koletsi et al. 2020</xref>).</p>
              <p>According to available results from in vitro studies, CPC has shown promising antiviral
effects against SARS-CoV-2 (<xref rid="bibr20-00220345231156415" ref-type="bibr">Koch-Heier
et al. 2021</xref>; <xref rid="bibr31-00220345231156415" ref-type="bibr">Muñoz-Basagoiti
et al. 2021</xref>; <xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al.
2022</xref>). For instance, Meister et al. evaluated a wide range of antiseptics for their
efficacy to SARS-CoV-2 in vitro and found that CPC, benzalkonium chloride (BAC),
polyvenylpyrrolidone iodine (PVP-I), and a mixture of surfactants showed strong
dose-dependent reductions of SARS-CoV-2 infectivity, exerted through disruption of the virus
envelope (<xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>).
BAC was then investigated as mouthwash in a randomized placebo-controlled clinical trial,
but the high antiviral efficacy found in vitro translated to only mild and nonsignificant
effects on viral load and infectivity in clinics, probably related to the rather low sample
size, particularly for virus rescue in cell culture (<xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>). However, it was proposed that
combinations of antiseptics as usually sold in commercial products may yield higher efficacy
(<xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>) and
could provide synergistic effects (<xref rid="bibr20-00220345231156415" ref-type="bibr">Koch-Heier et al. 2021</xref>).</p>
              <p>When assessing the effects of the mouthwash on viral loads, we found slight reductions in
both groups. Despite statistical significance found for the 0.8 log<sub>10</sub> reduction
in the test group, this may mainly be attributed to the mechanical effect inherent to
rinsing and gargling rather than to antiseptic action, as we observed a similar trend
(reduction by 0.4 log<sub>10</sub>) in the placebo group gargling with 0.9% NaCl.
Furthermore, the baseline viral load in the test group was about 0.5 log<sub>10</sub> RNA
copies/mL higher than in the placebo group, which may have also influenced the results and
could be considered a potential limitation of the randomization process based on a
computer-generated randomization table that did not consider the vaccination status and
history of COVID-19 infection in the included patients. <xref rid="bibr4-00220345231156415" ref-type="bibr">Barrueco et al. (2022)</xref> also detected a significant
decrease in the mean values of viral load 1 h after rinsing only in the placebo group.
Furthermore, CPC does not affect the integrity of viral RNA but the viral envelope (<xref rid="bibr31-00220345231156415" ref-type="bibr">Muñoz-Basagoiti et al. 2021</xref>; <xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>). Therefore,
qRT-PCR cannot be considered a sufficient method to evaluate the clinical efficacy of
antiseptics such as CPC against SARS-CoV-2 (<xref rid="bibr14-00220345231156415" ref-type="bibr">Gottsauner et al. 2020</xref>; <xref rid="bibr12-00220345231156415" ref-type="bibr">Ferrer et al. 2021</xref>; <xref rid="bibr4-00220345231156415" ref-type="bibr">Barrueco et al. 2022</xref>; <xref rid="bibr8-00220345231156415" ref-type="bibr">Cieplik and Jakubovics 2022</xref>; <xref rid="bibr26-00220345231156415" ref-type="bibr">Meister et al. 2022</xref>).</p>
              <p>The successful rescue of SARS-CoV-2 in cell culture is very challenging and strongly
correlates with high viral load in the samples (&gt;10<sup>7</sup> RNA copies/mL), positive
detection of viral antigen, and short period after symptom onset (<xref rid="bibr13-00220345231156415" ref-type="bibr">Gniazdowski et al. 2020</xref>; <xref rid="bibr39-00220345231156415" ref-type="bibr">Wölfel et al. 2020</xref>; <xref rid="bibr6-00220345231156415" ref-type="bibr">Buder et al. 2021</xref>; <xref rid="bibr15-00220345231156415" ref-type="bibr">Hakki et al. 2022</xref>). Therefore, positive antigen
point-of-care tests and symptom onset within the last 72 h were inclusion criteria for the
present study, but still SARS-CoV-2 could not be successfully cultured from all baseline
oropharyngeal specimens, reducing sample size to 6 (test group) or 9 patients (control
group), which can be considered a limitation of the present study. When comparing viral
infectivity at baseline and 30 min after the test mouthwash, there was a significant
decrease by 1.4 log<sub>10</sub>. Very recently, <xref rid="bibr4-00220345231156415" ref-type="bibr">Barrueco et al. (2022)</xref> assessed the effects of 4
commercially available antiseptic mouthwashes, including 1 containing 0.07% CPC in a
randomized controlled clinical trial, and performed virus rescue in cell culture for
assessing viral infectivity from saliva specimens obtained at baseline and 30 or 60 min
following the mouthwash. They observed a significant decrease of 1.5 log genome copies/mL 60
min after the CPC-containing mouthwash, similar to our results 30 min after the mouthwash
(1.4 log<sub>10</sub> PFU/mL), but found no reduction at the shorter period of 30 min (<xref rid="bibr4-00220345231156415" ref-type="bibr">Barrueco et al. 2022</xref>). These results
are in line with another recent study by <xref rid="bibr1-00220345231156415" ref-type="bibr">Alemany et al. (2022)</xref>, who performed a randomized controlled clinical trial
investigating a commercially available mouthwash containing 0.07% CPC as active ingredient.
Despite not performing virus culture, they described a surrogate for virus particle
degradation by modifying a commercially available enzyme-linked immunosorbent assay for the
SARS-CoV-2 nucleocapsid protein. By omitting the step of membrane lysis, increased detection
of nucleocapsid indicates destruction of the viral envelope by the mouthwash or its active
ingredient CPC. Indeed, the levels of SARS-CoV-2 nucleocapsid protein were significantly
higher in the test group 1 and 3 h following the mouthwash than in the placebo group (<xref rid="bibr1-00220345231156415" ref-type="bibr">Alemany et al. 2022</xref>). In synopsis of
these 2 studies and the present one, there is growing evidence that preprocedural
mouthwashes containing CPC may exert some antiviral effects on SARS-CoV-2. Notably, we
observed at least a trend toward reduced infectivity after gargling with 0.9% NaCl, so the
process of gargling alone seems to have an effect. It must further be considered that it is
still unclear whether the observed reductions of SARS-CoV-2 infectivity after gargling with
mouthwashes containing CPC or other active ingredients can lead to clinically relevant
reductions in the risk of transmission of SARS-CoV-2 (<xref rid="bibr8-00220345231156415" ref-type="bibr">Cieplik and Jakubovics 2022</xref>). Furthermore, it must be
kept in mind that the frequent use of antiseptics may also exert some negative effects such
as inducing potentially detrimental ecological shifts in the oral microbiota (<xref rid="bibr23-00220345231156415" ref-type="bibr">Mao et al. 2022</xref>) or development of
antiseptic resistance in oral bacteria (<xref rid="bibr38-00220345231156415" ref-type="bibr">Verspecht et al. 2019</xref>; <xref rid="bibr3-00220345231156415" ref-type="bibr">Auer et
al. 2022</xref>; <xref rid="bibr30-00220345231156415" ref-type="bibr">Muehler et al.
2022</xref>).</p>
              <p>Besides the main scope of the present study, we also assessed the viral load and viral
infectivity of the baseline oropharyngeal specimens with respect to the COVID-19 vaccination
status of the included patients. Interestingly, we found that the samples from individuals
with 3 vaccine shots exhibited significantly less infectious particles than those with just
2 vaccine shots. IgA and IgG neutralizing antibodies (nAbs) have been detected in the saliva
of patients vaccinated with 2 shots of messenger RNA–based vaccines (<xref rid="bibr19-00220345231156415" ref-type="bibr">Ketas et al. 2021</xref>; <xref rid="bibr29-00220345231156415" ref-type="bibr">Mostaghimi et al. 2021</xref>). However, while the nAb
titers continuously decrease over a period of 6 to 8 mo following the second vaccination
dose, a third vaccine shot (as “booster” about 6 mo after the second shot) increases the nAb
titers again for a certain period (<xref rid="bibr36-00220345231156415" ref-type="bibr">Sette and Crotty 2022</xref>). Since the interval to the last vaccination was shorter in
patients with 3 shots than in those with 2, this could explain the lower infectivity found
in samples from those patients who had received this booster vaccination.</p>
            </sec>
            <sec sec-type="conclusions" id="section16-00220345231156415">
              <title>Conclusion</title>
              <p>The present study indicates that gargling mouth and throat with a commercial mouthwash
containing 0.05% CPC and 0.05% CHX could slightly but significantly reduce viral load in
SARS-CoV-2–positive patients. Despite a small sample size, the test mouthwash also
significantly reduced viral infectivity, while notably, gargling with 0.9% NaCl also had a
slight effect. These findings add some further evidence for a potential effect of
CPC-containing mouthwashes on reducing SARS-CoV-2 infectivity, although further studies with
larger sample sizes are needed to corroborate these results.</p>
            </sec>
            <sec id="section17-00220345231156415">
              <title>Author Contributions</title>
              <p>E.L. Bonn, contributed to data acquisition, analysis and interpretation, drafted and
critically revised the manuscript; A. Rohrhofer, contributed to data analysis, critically
revised the manuscript; F.-X. Audebert, contributed to conception and design, data
acquisition and interpretation, critically revised the manuscript; H. Lang, contributed to
conception and design, data acquisition, critically revised the manuscript; D.L. Auer,
contributed to acquisition, analysis and interpretation, critically revised the manuscript;
K.J. Scholz, P. Schuster, B. Schmidt, contributed to conception and design, data analysis
and interpretation, critically revised the manuscript; J.J. Wenzel, K.-A. Hiller,
contributed to data analysis and interpretation, critically revised the manuscript; W.
Buchalla, J.-M. Gottsauner, V. Vielsmeier, contributed to conception and design, data
interpretation, critically revised the manuscript; F. Cieplik, contributed to conception and
design, data analysis and interpretation, drafted and critically revised the manuscript. All
authors gave their final approval and agree to be accountable for all aspects of the
work.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank the team of the Praxiszentrum Alte Mälzerei and all patients who volunteered to
participate in this study.</p>
            </ack>
            <fn-group>
              <fn fn-type="COI-statement">
                <p>The authors declared no potential conflicts of interest with respect to the research,
authorship, and/or publication of this article.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research,
authorship, and/or publication of this article: This study was an investigator-initiated
trial funded in part by Dentaid SL. The funder had no role in the design and conduct of
the study or the decision to prepare and submit the manuscript for publication. F. Cieplik
received consultation honoraria from Dentaid SL. Financial support was also provided
through the pandemic responsiveness fund of the Bavarian Ministry of Science and Art (to
B. Schmidt) and by the Deutsche Forschungsgemeinschaft (DFG; grant CI 263/3-1 to F.
Cieplik).</p>
              </fn>
              <fn fn-type="other">
                <p><bold>ORCID iDs:</bold> J.M. Gottsauner <inline-graphic xlink:href="10.1177_00220345231156415-img1.jpg"/><ext-link xlink:href="https://orcid.org/0000-0003-3623-3183" ext-link-type="uri">https://orcid.org/0000-0003-3623-3183</ext-link></p>
                <p>F. Cieplik <inline-graphic xlink:href="10.1177_00220345231156415-img1.jpg"/><ext-link xlink:href="https://orcid.org/0000-0002-1750-7380" ext-link-type="uri">https://orcid.org/0000-0002-1750-7380</ext-link></p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bibr1-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alemany</surname><given-names>A</given-names></name><name><surname>Perez-Zsolt</surname><given-names>D</given-names></name><name><surname>Raïch-Regué</surname><given-names>D</given-names></name><name><surname>Muñoz-Basagoiti</surname><given-names>J</given-names></name><name><surname>Ouchi</surname><given-names>D</given-names></name><name><surname>Laporte-Villar</surname><given-names>C</given-names></name><name><surname>Baro</surname><given-names>B</given-names></name><name><surname>Henríquez</surname><given-names>N</given-names></name><name><surname>Prat</surname><given-names>N</given-names></name><name><surname>Gianinetto</surname><given-names>MO</given-names></name></person-group>, <etal>et al</etal>. <year>2022</year>. <article-title>Cetylpyridinium
chloride mouthwash to reduce shedding of infectious SARS-CoV-2: a double-blind
randomized clinical trial</article-title>. <source>J Dent Res</source>.
<volume>101</volume>(<issue>12</issue>):<fpage>1450</fpage>–<lpage>1456</lpage>.<pub-id pub-id-type="pmid">35727681</pub-id></mixed-citation>
              </ref>
              <ref id="bibr2-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname><given-names>MWB</given-names></name><name><surname>Estrich</surname><given-names>CG</given-names></name><name><surname>Mikkelsen</surname><given-names>M</given-names></name><name><surname>Morrissey</surname><given-names>R</given-names></name><name><surname>Harrison</surname><given-names>B</given-names></name><name><surname>Geisinger</surname><given-names>ML</given-names></name><name><surname>Ioannidou</surname><given-names>E</given-names></name><name><surname>Vujicic</surname><given-names>M</given-names></name></person-group>. <year>2021</year>. <article-title>COVID-2019 among dentists in the United
States: a 6-month longitudinal report of accumulative prevalence and
incidence</article-title>. <source>J Am Dent Assoc</source>.
<volume>152</volume>(<issue>6</issue>):<fpage>425</fpage>–<lpage>433</lpage>.<pub-id pub-id-type="pmid">34044974</pub-id></mixed-citation>
              </ref>
              <ref id="bibr3-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auer</surname><given-names>DL</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name><name><surname>Muehler</surname><given-names>D</given-names></name><name><surname>Wittmer</surname><given-names>A</given-names></name><name><surname>Ohle</surname><given-names>C</given-names></name><name><surname>von, Wolff</surname><given-names>D</given-names></name><name><surname>Frese</surname><given-names>C</given-names></name><name><surname>Hiller</surname><given-names>K-A</given-names></name><name><surname>Maisch</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <year>2022</year>. <article-title>Phenotypic
adaptation to antiseptics and effects on biofilm formation capacity and antibiotic
resistance in clinical isolates of early colonizers in dental plaque</article-title>.
<source>Antibiotics</source>.
<volume>11</volume>(<issue>5</issue>):<fpage>688</fpage>.<pub-id pub-id-type="pmid">35625332</pub-id></mixed-citation>
              </ref>
              <ref id="bibr4-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrueco</surname><given-names>ÁS</given-names></name><name><surname>Mateos-Moreno</surname><given-names>MV</given-names></name><name><surname>Martínez-Beneyto</surname><given-names>Y</given-names></name><name><surname>García-Vázquez</surname><given-names>E</given-names></name><name><surname>González</surname><given-names>AC</given-names></name><name><surname>Ferrero</surname><given-names>JZ</given-names></name><name><surname>Castaño</surname><given-names>AB</given-names></name><name><surname>Rueda</surname><given-names>IA</given-names></name><name><surname>Aubá</surname><given-names>JMV</given-names></name><name><surname>Español</surname><given-names>CC</given-names></name></person-group>, <etal>et al</etal>. <year>2022</year>. <article-title>Effect of oral
antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind
clinical trial</article-title>. <source>Emerg Microbes Infec</source>.
<volume>11</volume>(<issue>1</issue>):<fpage>1833</fpage>–<lpage>1842</lpage>.<pub-id pub-id-type="pmid">35796097</pub-id></mixed-citation>
              </ref>
              <ref id="bibr5-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bidra</surname><given-names>AS</given-names></name><name><surname>Pelletier</surname><given-names>JS</given-names></name><name><surname>Westover</surname><given-names>JB</given-names></name><name><surname>Frank</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>SM</given-names></name><name><surname>Tessema</surname><given-names>B</given-names></name></person-group>. <year>2020</year>. <article-title>Comparison of in vitro inactivation of
SARS CoV-2 with hydrogen peroxide and povidone-iodine oral antiseptic
rinses</article-title>. <source>J Prosthodont</source>.
<volume>29</volume>(<issue>7</issue>):<fpage>599</fpage>–<lpage>603</lpage>.<pub-id pub-id-type="pmid">32608097</pub-id></mixed-citation>
              </ref>
              <ref id="bibr6-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buder</surname><given-names>F</given-names></name><name><surname>Bauswein</surname><given-names>M</given-names></name><name><surname>Magnus</surname><given-names>CL</given-names></name><name><surname>Audebert</surname><given-names>F</given-names></name><name><surname>Lang</surname><given-names>H</given-names></name><name><surname>Kundel</surname><given-names>C</given-names></name><name><surname>Distler</surname><given-names>K</given-names></name><name><surname>Reuschel</surname><given-names>E</given-names></name><name><surname>Lubnow</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>. <year>2021</year>. <article-title>SARS-CoV-2
infectivity correlates with high viral loads and detection of viral antigen and is
terminated by seroconversion</article-title>. <source>J Infect Dis</source>.
<volume>225</volume>(<issue>2</issue>):jiab415.</mixed-citation>
              </ref>
              <ref id="bibr7-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhary</surname><given-names>P</given-names></name><name><surname>Melkonyan</surname><given-names>A</given-names></name><name><surname>Meethil</surname><given-names>A</given-names></name><name><surname>Saraswat</surname><given-names>S</given-names></name><name><surname>Hall</surname><given-names>DL</given-names></name><name><surname>Cottle</surname><given-names>J</given-names></name><name><surname>Wenzel</surname><given-names>M</given-names></name><name><surname>Ayouty</surname><given-names>N</given-names></name><name><surname>Bense</surname><given-names>S</given-names></name><name><surname>Casanova</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>. <year>2021</year>. <article-title>Estimating salivary
carriage of severe acute respiratory syndrome coronavirus 2 in nonsymptomatic people and
efficacy of mouthrinse in reducing viral load</article-title>. <source>J Am Dent
Assoc</source>.
<volume>152</volume>(<issue>11</issue>):<fpage>903</fpage>–<lpage>908</lpage>.<pub-id pub-id-type="pmid">34561086</pub-id></mixed-citation>
              </ref>
              <ref id="bibr8-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cieplik</surname><given-names>F</given-names></name><name><surname>Jakubovics</surname><given-names>NS</given-names></name></person-group>. <year>2022</year>. <article-title>Preprocedural mouthwashes for reduction
of SARS-CoV-2 viral load and infectivity</article-title>. <source>J Dent Res</source>.
<volume>101</volume>(<issue>12</issue>):<fpage>1421</fpage>–<lpage>1423</lpage>.<pub-id pub-id-type="pmid">35897159</pub-id></mixed-citation>
              </ref>
              <ref id="bibr9-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cieplik</surname><given-names>F</given-names></name><name><surname>Jakubovics</surname><given-names>NS</given-names></name><name><surname>Buchalla</surname><given-names>W</given-names></name><name><surname>Maisch</surname><given-names>T</given-names></name><name><surname>Hellwig</surname><given-names>E</given-names></name><name><surname>Al-Ahmad</surname><given-names>A</given-names></name></person-group>. <year>2019</year>. <article-title>Resistance toward chlorhexidine in oral
bacteria—is there cause for concern?</article-title><source>Front Microbiol</source>.
<volume>10</volume>:<fpage>587</fpage>.<pub-id pub-id-type="pmid">30967854</pub-id></mixed-citation>
              </ref>
              <ref id="bibr10-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Landt</surname><given-names>O</given-names></name><name><surname>Kaiser</surname><given-names>M</given-names></name><name><surname>Molenkamp</surname><given-names>R</given-names></name><name><surname>Meijer</surname><given-names>A</given-names></name><name><surname>Chu</surname><given-names>DK</given-names></name><name><surname>Bleicker</surname><given-names>T</given-names></name><name><surname>Brünink</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>ML</given-names></name></person-group>, <etal>et al</etal>. <year>2020</year>. <article-title>Detection of 2019
novel coronavirus (2019-nCoV) by real-time RT-PCR</article-title>. <source>Euro
Surveill</source>.
<volume>25</volume>(<issue>3</issue>):<fpage>2000045</fpage>.<pub-id pub-id-type="pmid">31992387</pub-id></mixed-citation>
              </ref>
              <ref id="bibr11-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domênico</surname><given-names>MBD</given-names></name><name><surname>Cesca</surname><given-names>H</given-names></name><name><surname>Ponciano</surname><given-names>THJ</given-names></name><name><surname>Dos Santos</surname><given-names>RB</given-names></name><name><surname>Lenz</surname><given-names>U</given-names></name><name><surname>Antunes</surname><given-names>VP</given-names></name><name><surname>Godinho</surname><given-names>VW</given-names></name><name><surname>Collares</surname><given-names>K</given-names></name><name><surname>Corazza</surname><given-names>PH</given-names></name></person-group>. <year>2021</year>. <article-title>Effectiveness of hydrogen peroxide as
auxiliary treatment for hospitalized COVID-19 patients in Brazil: preliminary results of
a randomized double-blind clinical trial</article-title>. <source>Epidemiol
Health</source>. <volume>43</volume>:e2021032.</mixed-citation>
              </ref>
              <ref id="bibr12-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>MD</given-names></name><name><surname>Barrueco</surname><given-names>ÁS</given-names></name><name><surname>Martinez-Beneyto</surname><given-names>Y</given-names></name><name><surname>Mateos-Moreno</surname><given-names>MV</given-names></name><name><surname>Ausina-Márquez</surname><given-names>V</given-names></name><name><surname>García-Vázquez</surname><given-names>E</given-names></name><name><surname>Puche-Torres</surname><given-names>M</given-names></name><name><surname>Giner</surname><given-names>MJF</given-names></name><name><surname>González</surname><given-names>AC</given-names></name><name><surname>Coello</surname><given-names>JMS</given-names></name></person-group>, <etal>et al</etal>. <year>2021</year>. <article-title>Clinical evaluation
of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2</article-title>.
<source>Sci Rep</source>.
<volume>11</volume>(<issue>1</issue>):<fpage>24392</fpage>.<pub-id pub-id-type="pmid">34937855</pub-id></mixed-citation>
              </ref>
              <ref id="bibr13-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gniazdowski</surname><given-names>V</given-names></name><name><surname>Morris</surname><given-names>CP</given-names></name><name><surname>Wohl</surname><given-names>S</given-names></name><name><surname>Mehoke</surname><given-names>T</given-names></name><name><surname>Ramakrishnan</surname><given-names>S</given-names></name><name><surname>Thielen</surname><given-names>P</given-names></name><name><surname>Powell</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Armstrong</surname><given-names>DT</given-names></name><name><surname>Herrera</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <year>2020</year>. <article-title>Repeated
coronavirus disease 2019 molecular testing: correlation of severe acute respiratory
syndrome coronavirus 2 culture with molecular assays and cycle
thresholds</article-title>. <source>Clin Infect Dis</source>.
<volume>73</volume>(<issue>4</issue>):e860–e869.</mixed-citation>
              </ref>
              <ref id="bibr14-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottsauner</surname><given-names>MJ</given-names></name><name><surname>Michaelides</surname><given-names>I</given-names></name><name><surname>Schmidt</surname><given-names>B</given-names></name><name><surname>Scholz</surname><given-names>KJ</given-names></name><name><surname>Buchalla</surname><given-names>W</given-names></name><name><surname>Widbiller</surname><given-names>M</given-names></name><name><surname>Hitzenbichler</surname><given-names>F</given-names></name><name><surname>Ettl</surname><given-names>T</given-names></name><name><surname>Reichert</surname><given-names>TE</given-names></name><name><surname>Bohr</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>. <year>2020</year>. <article-title>A prospective
clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral
viral load of SARS-CoV-2</article-title>. <source>Clin Oral Investig</source>.
<volume>24</volume>(<issue>10</issue>):<fpage>3707</fpage>–<lpage>3713</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr15-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakki</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Jonnerby</surname><given-names>J</given-names></name><name><surname>Singanayagam</surname><given-names>A</given-names></name><name><surname>Barnett</surname><given-names>JL</given-names></name><name><surname>Madon</surname><given-names>KJ</given-names></name><name><surname>Koycheva</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Houston</surname><given-names>H</given-names></name><name><surname>Nevin</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>; <collab>ATACCC study investigators</collab>.
<year>2022</year>. <article-title>Onset and window of SARS-CoV-2 infectiousness and
temporal correlation with symptom onset: a prospective, longitudinal, community cohort
study</article-title>. <source>Lancet Respir Med</source>.
<volume>10</volume>(<issue>11</issue>):<fpage>1061</fpage>–<lpage>1073</lpage>.<pub-id pub-id-type="pmid">35988572</pub-id></mixed-citation>
              </ref>
              <ref id="bibr16-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>D</given-names></name><name><surname>Serrano</surname><given-names>J</given-names></name><name><surname>Roldán</surname><given-names>S</given-names></name><name><surname>Sanz</surname><given-names>M</given-names></name></person-group>. <year>2020</year>. <article-title>Is the oral cavity relevant in
SARS-CoV-2 pandemic?</article-title><source>Clin Oral Invest</source>.
<volume>24</volume>(<issue>8</issue>):<fpage>2925</fpage>–<lpage>2930</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr17-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Huang</surname><given-names>JT</given-names></name></person-group>. <year>2021</year>. <article-title>Use of chlorhexidine to eradicate
oropharyngeal SARS-CoV-2 in COVID-19 patients</article-title>. <source>J Med
Virol</source>.
<volume>93</volume>(<issue>7</issue>):<fpage>4370</fpage>–<lpage>4373</lpage>.<pub-id pub-id-type="pmid">33755218</pub-id></mixed-citation>
              </ref>
              <ref id="bibr18-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakubovics</surname><given-names>NS</given-names></name><name><surname>Goodman</surname><given-names>SD</given-names></name><name><surname>Mashburn-Warren</surname><given-names>L</given-names></name><name><surname>Stafford</surname><given-names>GP</given-names></name><name><surname>Cieplik</surname><given-names>F</given-names></name></person-group>. <year>2021</year>. <article-title>The dental plaque biofilm
matrix</article-title>. <source>Periodontol</source><year>2000</year>.
<volume>86</volume>(<issue>1</issue>):<fpage>32</fpage>–<lpage>56</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr19-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ketas</surname><given-names>TJ</given-names></name><name><surname>Chaturbhuj</surname><given-names>D</given-names></name><name><surname>Portillo</surname><given-names>VMC</given-names></name><name><surname>Francomano</surname><given-names>E</given-names></name><name><surname>Golden</surname><given-names>E</given-names></name><name><surname>Chandrasekhar</surname><given-names>S</given-names></name><name><surname>Debnath</surname><given-names>G</given-names></name><name><surname>Diaz-Tapia</surname><given-names>R</given-names></name><name><surname>Yasmeen</surname><given-names>A</given-names></name><name><surname>Kramer</surname><given-names>KD</given-names></name></person-group>, <etal>et al</etal>. <year>2021</year>. <article-title>Antibody responses
to SARS-CoV-2 mRNA vaccines are detectable in saliva</article-title>. <source>Pathogens
Immun</source>.
<volume>6</volume>(<issue>1</issue>):<fpage>116</fpage>–<lpage>134</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr20-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch-Heier</surname><given-names>J</given-names></name><name><surname>Hoffmann</surname><given-names>H</given-names></name><name><surname>Schindler</surname><given-names>M</given-names></name><name><surname>Lussi</surname><given-names>A</given-names></name><name><surname>Planz</surname><given-names>O</given-names></name></person-group>. <year>2021</year>. <article-title>Inactivation of SARS-CoV-2 through
treatment with the mouth rinsing solutions ViruProX<sup>®</sup> and BacterX<sup>®</sup>
Pro</article-title>. <source>Microorganisms</source>.
<volume>9</volume>(<issue>3</issue>):<fpage>521</fpage>.<pub-id pub-id-type="pmid">33802603</pub-id></mixed-citation>
              </ref>
              <ref id="bibr21-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koletsi</surname><given-names>D</given-names></name><name><surname>Belibasakis</surname><given-names>GN</given-names></name><name><surname>Eliades</surname><given-names>T</given-names></name></person-group>. <year>2020</year>. <article-title>Interventions to reduce aerosolized
microbes in dental practice: a systematic review with network meta-analysis of
randomized controlled trials</article-title>. <source>J Dent Res</source>.
<volume>99</volume>(<issue>11</issue>):<fpage>1228</fpage>–<lpage>1238</lpage>.<pub-id pub-id-type="pmid">32660314</pub-id></mixed-citation>
              </ref>
              <ref id="bibr22-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Auer</surname><given-names>DL</given-names></name><name><surname>Buchalla</surname><given-names>W</given-names></name><name><surname>Hiller</surname><given-names>K-A</given-names></name><name><surname>Maisch</surname><given-names>T</given-names></name><name><surname>Hellwig</surname><given-names>E</given-names></name><name><surname>Al-Ahmad</surname><given-names>A</given-names></name><name><surname>Cieplik</surname><given-names>F</given-names></name></person-group>. <year>2020</year>. <article-title>Cetylpyridinium chloride: mechanism of
action, antimicrobial efficacy in biofilms, and potential risks of
resistance</article-title>. <source>Antimicrob Agents Chemother</source>.
<volume>64</volume>(<issue>8</issue>):e00576-20.</mixed-citation>
              </ref>
              <ref id="bibr23-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Hiergeist</surname><given-names>A</given-names></name><name><surname>Auer</surname><given-names>DL</given-names></name><name><surname>Scholz</surname><given-names>KJ</given-names></name><name><surname>Muehler</surname><given-names>D</given-names></name><name><surname>Hiller</surname><given-names>K-A</given-names></name><name><surname>Maisch</surname><given-names>T</given-names></name><name><surname>Buchalla</surname><given-names>W</given-names></name><name><surname>Hellwig</surname><given-names>E</given-names></name><name><surname>Gessner</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <year>2022</year>. <article-title>Ecological effects
of daily antiseptic treatment on microbial composition of saliva-grown microcosm
biofilms and selection of resistant phenotypes</article-title>. <source>Front
Microbiol</source>. <volume>13</volume>:<fpage>934525</fpage>.<pub-id pub-id-type="pmid">35847089</pub-id></mixed-citation>
              </ref>
              <ref id="bibr24-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marui</surname><given-names>VC</given-names></name><name><surname>Souto</surname><given-names>MLS</given-names></name><name><surname>Rovai</surname><given-names>ES</given-names></name><name><surname>Romito</surname><given-names>GA</given-names></name><name><surname>Chambrone</surname><given-names>L</given-names></name><name><surname>Pannuti</surname><given-names>CM</given-names></name></person-group>. <year>2019</year>. <article-title>Efficacy of preprocedural mouthrinses
in the reduction of microorganisms in aerosol: a systematic review</article-title>.
<source>J Am Dent Assoc</source>.
<volume>150</volume>(<issue>12</issue>):1015–1026.e1.</mixed-citation>
              </ref>
              <ref id="bibr25-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meister</surname><given-names>TL</given-names></name><name><surname>Brüggemann</surname><given-names>Y</given-names></name><name><surname>Todt</surname><given-names>D</given-names></name><name><surname>Conzelmann</surname><given-names>C</given-names></name><name><surname>Müller</surname><given-names>JA</given-names></name><name><surname>Groß</surname><given-names>R</given-names></name><name><surname>Münch</surname><given-names>J</given-names></name><name><surname>Krawczyk</surname><given-names>A</given-names></name><name><surname>Steinmann</surname><given-names>J</given-names></name><name><surname>Steinmann</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <year>2020</year>. <article-title>Virucidal efficacy
of different oral rinses against severe acute respiratory syndrome coronavirus
2</article-title>. <source>J Infect Dis</source>.
<volume>222</volume>(<issue>8</issue>):<fpage>1289</fpage>–<lpage>1292</lpage>.<pub-id pub-id-type="pmid">32726430</pub-id></mixed-citation>
              </ref>
              <ref id="bibr26-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meister</surname><given-names>TL</given-names></name><name><surname>Gottsauner</surname><given-names>J-M</given-names></name><name><surname>Schmidt</surname><given-names>B</given-names></name><name><surname>Heinen</surname><given-names>N</given-names></name><name><surname>Todt</surname><given-names>D</given-names></name><name><surname>Audebert</surname><given-names>F</given-names></name><name><surname>Buder</surname><given-names>F</given-names></name><name><surname>Lang</surname><given-names>H</given-names></name><name><surname>Gessner</surname><given-names>A</given-names></name><name><surname>Steinmann</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. <year>2022</year>. <article-title>Mouthrinses against
SARS-CoV-2—high antiviral effectivity by membrane disruption in vitro translates to mild
effects in a randomized placebo-controlled clinical trial</article-title>. <source>Virus
Res</source>. <volume>316</volume>:<fpage>198791</fpage>.<pub-id pub-id-type="pmid">35504446</pub-id></mixed-citation>
              </ref>
              <ref id="bibr27-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Hua</surname><given-names>F</given-names></name><name><surname>Bian</surname><given-names>Z</given-names></name></person-group>. <year>2020</year>. <article-title>Coronavirus disease 2019 (COVID-19):
emerging and future challenges for dental and oral medicine</article-title>. <source>J
Dent Res</source>.
<volume>99</volume>(<issue>5</issue>):<fpage>481</fpage>–<lpage>487</lpage>.<pub-id pub-id-type="pmid">32162995</pub-id></mixed-citation>
              </ref>
              <ref id="bibr28-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mksoud</surname><given-names>M</given-names></name><name><surname>Ittermann</surname><given-names>T</given-names></name><name><surname>Holtfreter</surname><given-names>B</given-names></name><name><surname>Söhnel</surname><given-names>A</given-names></name><name><surname>Söhnel</surname><given-names>C</given-names></name><name><surname>Welk</surname><given-names>A</given-names></name><name><surname>Ulm</surname><given-names>L</given-names></name><name><surname>Becker</surname><given-names>K</given-names></name><name><surname>Hübner</surname><given-names>N-O</given-names></name><name><surname>Rau</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <year>2022</year>. <article-title>Prevalence of
SARS-CoV-2 IgG antibodies among dental teams in Germany</article-title>. <source>Clin
Oral Invest</source>.
<volume>26</volume>(<issue>5</issue>):<fpage>3965</fpage>–<lpage>3974</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr29-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostaghimi</surname><given-names>D</given-names></name><name><surname>Valdez</surname><given-names>CN</given-names></name><name><surname>Larson</surname><given-names>HT</given-names></name><name><surname>Kalinich</surname><given-names>CC</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group>. <year>2021</year>. <article-title>Prevention of host-to-host transmission
by SARS-CoV-2 vaccines</article-title>. <source>Lancet Infect Dis</source>.
<volume>22</volume>(<issue>2</issue>):e52–e58.</mixed-citation>
              </ref>
              <ref id="bibr30-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muehler</surname><given-names>D</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Czemmel</surname><given-names>S</given-names></name><name><surname>Geißert</surname><given-names>J</given-names></name><name><surname>Engesser</surname><given-names>C</given-names></name><name><surname>Hiller</surname><given-names>K-A</given-names></name><name><surname>Widbiller</surname><given-names>M</given-names></name><name><surname>Maisch</surname><given-names>T</given-names></name><name><surname>Buchalla</surname><given-names>W</given-names></name><name><surname>Al-Ahmad</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. <year>2022</year>. <article-title>Transcriptomic
stress response in Streptococcus mutans following treatment with a sublethal
concentration of chlorhexidine digluconate</article-title>.
<source>Microorganisms</source>.
<volume>10</volume>(<issue>3</issue>):<fpage>561</fpage>.<pub-id pub-id-type="pmid">35336136</pub-id></mixed-citation>
              </ref>
              <ref id="bibr31-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muñoz-Basagoiti</surname><given-names>J</given-names></name><name><surname>Perez-Zsolt</surname><given-names>D</given-names></name><name><surname>León</surname><given-names>R</given-names></name><name><surname>Blanc</surname><given-names>V</given-names></name><name><surname>Raïch-Regué</surname><given-names>D</given-names></name><name><surname>Cano-Sarabia</surname><given-names>M</given-names></name><name><surname>Trinité</surname><given-names>B</given-names></name><name><surname>Pradenas</surname><given-names>E</given-names></name><name><surname>Blanco</surname><given-names>J</given-names></name><name><surname>Gispert</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <year>2021</year>. <article-title>Mouthwashes with
CPC reduce the infectivity of SARS-CoV-2 variants in vitro</article-title>. <source>J
Dent Res</source>.
<volume>100</volume>(<issue>11</issue>):<fpage>1265</fpage>–<lpage>1272</lpage>.<pub-id pub-id-type="pmid">34282982</pub-id></mixed-citation>
              </ref>
              <ref id="bibr32-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>LH</given-names></name><name><surname>Drew</surname><given-names>DA</given-names></name><name><surname>Graham</surname><given-names>MS</given-names></name><name><surname>Joshi</surname><given-names>AD</given-names></name><name><surname>Guo</surname><given-names>C-G</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Mehta</surname><given-names>RS</given-names></name><name><surname>Warner</surname><given-names>ET</given-names></name><name><surname>Sikavi</surname><given-names>DR</given-names></name><name><surname>Lo</surname><given-names>C-H</given-names></name></person-group>, <etal>et al</etal>; <collab>Coronavirus Pandemic Epidemiology
Consortium</collab>. <year>2020</year>. <article-title>Risk of COVID-19 among front-line
health-care workers and the general community: a prospective cohort
study</article-title>. <source>Lancet Public Health</source>.
<volume>5</volume>(<issue>9</issue>):e475–e483.</mixed-citation>
              </ref>
              <ref id="bibr33-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name></person-group>. <year>2020</year>. <article-title>Transmission routes of 2019-nCoV and
controls in dental practice</article-title>. <source>Int J Oral Sci</source>.
<volume>12</volume>(<issue>1</issue>):<fpage>9</fpage>.<pub-id pub-id-type="pmid">32127517</pub-id></mixed-citation>
              </ref>
              <ref id="bibr34-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarapultseva</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Sarapultsev</surname><given-names>A</given-names></name></person-group>. <year>2021</year>. <article-title>SARS-CoV-2 seropositivity among dental
staff and the role of aspirating systems</article-title>. <source>JDR Clin Transl
Res</source>.
<volume>6</volume>(<issue>2</issue>):<fpage>132</fpage>–<lpage>138</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr35-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seneviratne</surname><given-names>CJ</given-names></name><name><surname>Balan</surname><given-names>P</given-names></name><name><surname>Ko</surname><given-names>KKK</given-names></name><name><surname>Udawatte</surname><given-names>NS</given-names></name><name><surname>Lai</surname><given-names>D</given-names></name><name><surname>Ng</surname><given-names>DHL</given-names></name><name><surname>Venkatachalam</surname><given-names>I</given-names></name><name><surname>Lim</surname><given-names>KS</given-names></name><name><surname>Ling</surname><given-names>ML</given-names></name><name><surname>Oon</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. <year>2021</year>. <article-title>Efficacy of
commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in
Singapore</article-title>. <source>Infection</source>.
<volume>49</volume>(<issue>2</issue>):<fpage>305</fpage>–<lpage>311</lpage>.<pub-id pub-id-type="pmid">33315181</pub-id></mixed-citation>
              </ref>
              <ref id="bibr36-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name></person-group>. <year>2022</year>. <article-title>Immunological memory to SARS-CoV-2
infection and COVID-19 vaccines</article-title>. <source>Immunol Rev</source>.
<volume>310</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">35733376</pub-id></mixed-citation>
              </ref>
              <ref id="bibr37-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Bushmaker</surname><given-names>T</given-names></name><name><surname>Morris</surname><given-names>DH</given-names></name><name><surname>Holbrook</surname><given-names>MG</given-names></name><name><surname>Gamble</surname><given-names>A</given-names></name><name><surname>Williamson</surname><given-names>BN</given-names></name><name><surname>Tamin</surname><given-names>A</given-names></name><name><surname>Harcourt</surname><given-names>JL</given-names></name><name><surname>Thornburg</surname><given-names>NJ</given-names></name><name><surname>Gerber</surname><given-names>SI</given-names></name></person-group>, <etal>et al</etal>. <year>2020</year>. <article-title>Aerosol and surface
stability of SARS-CoV-2 as compared with SARS-CoV-1</article-title>. <source>New Engl J
Med</source>.
<volume>382</volume>(<issue>16</issue>):<fpage>1564</fpage>–<lpage>1567</lpage>.<pub-id pub-id-type="pmid">32182409</pub-id></mixed-citation>
              </ref>
              <ref id="bibr38-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verspecht</surname><given-names>T</given-names></name><name><surname>Rodriguez Herrero</surname><given-names>E</given-names></name><name><surname>Khodaparast</surname><given-names>L</given-names></name><name><surname>Khodaparast</surname><given-names>L</given-names></name><name><surname>Boon</surname><given-names>N</given-names></name><name><surname>Bernaerts</surname><given-names>K</given-names></name><name><surname>Quirynen</surname><given-names>M</given-names></name><name><surname>Teughels</surname><given-names>W</given-names></name></person-group>. <year>2019</year>. <article-title>Development of antiseptic adaptation
and cross-adaptation in selected oral pathogens in vitro</article-title>. <source>Sci
Rep</source>. <volume>9</volume>(<issue>1</issue>):<fpage>8326</fpage>.<pub-id pub-id-type="pmid">31171824</pub-id></mixed-citation>
              </ref>
              <ref id="bibr39-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wölfel</surname><given-names>R</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Guggemos</surname><given-names>W</given-names></name><name><surname>Seilmaier</surname><given-names>M</given-names></name><name><surname>Zange</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Niemeyer</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>TC</given-names></name><name><surname>Vollmar</surname><given-names>P</given-names></name><name><surname>Rothe</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>. <year>2020</year>. <article-title>Virological
assessment of hospitalized patients with COVID-2019</article-title>.
<source>Nature</source>.
<volume>581</volume>(<issue>7809</issue>):<fpage>465</fpage>–<lpage>469</lpage>.<pub-id pub-id-type="pmid">32235945</pub-id></mixed-citation>
              </ref>
              <ref id="bibr40-00220345231156415">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Ruan</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <year>2020</year>. <article-title>SARS-CoV-2 viral
load in upper respiratory specimens of infected patients</article-title>. <source>New
Engl J Med</source>.
<volume>382</volume>(<issue>12</issue>):<fpage>1177</fpage>–<lpage>1179</lpage>.<pub-id pub-id-type="pmid">32074444</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
